Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Shanghai Zhongshan Hospital

ClinicalTrials.gov lists Shanghai Zhongshan Hospital as lead sponsor of 646 trials. It has 323 active development programs and 132 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

140 0 2004 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 120 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 140 in 2026 and about 120 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.

This page covers Shanghai Zhongshan Hospital: 646 lead-sponsored trials and 0 legal-entity registrations.

Get the Shanghai Zhongshan Hospital report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (298)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Liver Neoplasms 75
Carcinoma, Hepatocellular 66
Coronary Disease 39
Stomach Neoplasms 37
Coronary Artery Disease 35

Trials by start year as sponsor or collaborator (22)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 120
2025 102
2024 94
2023 54
2022 78
2021 91
2020 81
2019 51
2018 62
2017 45

Prediction, not a registry value: median of 36 months from start to primary completion across 90 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 114 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (323)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
TACE Liver Neoplasms Phase 3 7
TACE Carcinoma, Hepatocellular Phase 3 6
TORIPALIMAB Liver Neoplasms Phase 3 4
Transcatheter Arterial Chemoembolization Liver Neoplasms Phase 3 2
"Capecitabine" Cholangiocarcinoma Phase 3 2

Approved assets (132)

Shown in this order: max phase first.

Approved assets
Drug Trials
Metronidazole 6
(A)Bismuth 6
RABEPRAZOLE SODIUM 5
DEXMEDETOMIDINE 4
Dihydroartemisinin 4

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
68% hit target (n=63) 45% on time (n=64)

Journals published in (492)

Shown in this order: most published in first.

Journals published in
Journal Publications
The New England journal of medicine 69
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 50
Lancet (London, England) 41
The Lancet. Oncology 31
Annals of surgery 28

Organization relationships (97)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
West China Hospital Co sponsors trial with 14
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Co sponsors trial with 9
The First Affiliated Hospital with Nanjing Medical University Co sponsors trial with 8
Shanghai Pulmonary Hospital, Shanghai, China Co sponsors trial with 7
Shengjing Hospital Co sponsors trial with 5

Latest dated events (900)

Shown in this order: newest first.

Latest dated events
Date Event Source
2027-08 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-11-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-11-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-11-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (1,258)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ACE Trial collaborator Named in trial inclusion criteria
ACE Trial sponsor Named in trial inclusion criteria
AFP Trial sponsor Named in trial inclusion criteria
AFP Trial collaborator Named in trial inclusion criteria
AFP Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.